Compare Kaltura Inc (KLTR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Sanofi SA — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 478.1× Kaltura Inc's market cap, and Sanofi SA pays a 6.01% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Sanofi SA for 94 Days on average.
| KLTR | SNY | |
|---|---|---|
Market Cap | $199.08M | $95.18B |
Volume | 175,927 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $1.89 | $52.34 |
52-Week Low | $1.08 | $39.51 |
Typical Hold Time | 21 Days | 94 Days |
Enterprise Value | $211.29M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% with bearish technical signals. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though still unprofitable. Recent positive developments include AI platform recognition and major streaming contracts, while valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The outlook balances AI growth potential against persistent profitability challenges. Analyst consensus leans positive with 44% buy ratings, but high debt levels and negative cash flow present execution risks. The stock's direction hinges on AI monetization success and path to sustainable profitability.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
